Anti-CEA loaded maghemite nanoparticles as a theragnostic device for colorectal cancer

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5271-5282

  da Paz, Mariana Campos ^a   Almeida Santos, Maria de Fátima M ^a   Santos, Camila M B ^b   da Silva, Sebastião W ^b   de Souza, Lincoln Bernardo ^c   Lima, Emília C D ^c   Silva, Renata C ^a   Lucci, Carolina M ^a   Morais, Paulo César ^b   Azevedo, Ricardo B ^a   Lacava, Zulmira Guerrero Marques ^a  

^a Instituto de Ciencias Biologicas   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anti CEA antibody; Biocompatible device; Diagnostic; Magnetic nanoparticles; Raman; Targeted delivery

Indexed keywords

CARCINOEMBRYONIC ANTIBODY MAGHEMITE NANOPARTICLE CONJUGATE; CARCINOEMBRYONIC ANTIGEN; METAL NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOCOMPATIBILITY; CELL STRAIN HCT116; COLORECTAL CANCER; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY TEST; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MATERIAL COATING; NANOANALYSIS; NANODEVICE; PARTICLE SIZE; RAMAN SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FERRIC COMPOUNDS; HUMANS; MAGNETITE NANOPARTICLES; NANOCAPSULES;

EID: 84870359856     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32139     Document Type: Article

References (43)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Bünger S, Haug U, Kelly FM, etal. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen. 2011; 16(9):1018-1026.
3. Li M, Kim HS, Tian L, Yu MK, Jon S, Moon WK. Comparison of two ultrasmall superparamagnetic iron oxides on cytotoxicity and MR imaging of tumors. Theranostics. 2012;2(1):76-85.
4. Lim SW, Kim HW, Jun HY, etal. TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol. 2011;18(4):504-511.
5. Cheng L, Yang K, Li Y, etal. Multifunctional nanoparticles for upconversion luminescence/MR multimodal imaging and magnetically targeted photothermal therapy. Biomaterials. 2012;33(7):2215-2222.
6. Zhang L, Zhong X, Wang L, etal. T1-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging. 2011;33(1):194-202.
7. Portilho F, Estevanato L, Miranda-Vilela A, etal. Investigation of a magnetohyperthermia system efficacy. J Appl Phys. 2011;109(7): 07B307.
8. Balivada S, Rachakatla R, Wang H, etal. A/C magnetic hyperthermia of melanoma mediated by iron (0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer. 2010;10:119.
9. Carneiro ML, Nunes ES, Peixoto RC, etal. Free Rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy. J Nanobiotechnology. 2011;9:11.
10. Primo FL, Rodrigues MM, Simioni AR, Lacava ZG, Morais PC, Tedesco AC. Photosensitizer-loaded magnetic nanoemulsion for use in synergic photodynamic and magnetohyperthermia therapies of neoplastic cells. J Nanosci Nanotechnol. 2008;8(11):5873-5877.
11. Taylor RM, Huber DL, Monson TC, Ali AM, Bisoffi M, Sillerud LO. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res. 2011;13(10):4717-4729.
12. Quan G, Du X, Huo T, etal. Targeted molecular imaging of antigen OC183B2 in ovarian cancers using MR molecular probes. Acad Radiol. 2010;17(12):1468-1476.
13. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol. 2009;4(12):855-860.
14. Shimada R, Iinuma H, Akahane T, Horiuchi A, Watanabe T. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol Rep. 2012;27(4): 947-953.
15. Zhao YP, Ruan CP, Wang H, etal. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer. 2012;118(3):639-650.
16. Li M, Li JY, Zhao AL, etal. Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum. 2007; 50(11):1887-1898.
17. Artiko V, Petrović M, Sobić-Saranović D, etal. Radioimmunoscintigraphy of colorectal carcinomas with 99mTc-labelled antibodies. Hepatogastroenterology. 2011;58(106):347-351.
18. Aarts F, Boerman OC, Sharkey RM, etal. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F (ab') 2 antibody. Cancer. 2010;116(Suppl 4):1111-1117.
19. Frampas E, Maurel C, Remaud-Le Saëc P, etal. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging. 2011; 38(12):2153-2164.
20. Homayounfar K, Liersch T, Niessner M, etal. Multimodal treatment options for bilobar colorectal liver metastases. Langenbecks Arch Surg. 2010;395(6):633-641.
21. Valois CR, Braz JM, Nunes ES, etal. The effect of DMSA-functionalized magnetic nanoparticles on transendothelial migration of monocytes in the murine lung via a beta2integrin-dependent pathway. Biomaterials. 2010;31(2):366-374.
22. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30(29):5737-5750.
23. Fahlgren A, Baranov V, Frängsmyr L, Zoubir F, Hammarström ML, Hammarström S. Interferon-gamma tempers the expression of carcinoembryonic antigen family molecules in human colon cells: a possible role in innate mucosal defence. Scand J Immunol. 2003;58(6): 628-641.
24. Wang H, Rajagopal S, Reynolds S, Cederberg H, Chakrabarty S. Differentiation-promoting effect of 1-O (2methoxy) hexadecyl glycerol in human colon cancer cells. J Cell Physiol. 1999;178(2):173-178.
25. Kendall C, Day J, Hutchings J, etal. Evaluation of Raman probe for oesophageal cancer diagnostics. Analyst. 2010;135(12):3038-3041.
26. Wajed SA. Personalized treatment-the promise of molecular genetics diagnostics. J Gastrointest Surg. 2010;14 Suppl 1:S2-S5.
27. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther. 2010;128(2):324-335.
28. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm Res. 2012;29(5):1180-1188.
29. Kim BH, Lee N, Kim H, etal. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc. 2011; 133(32):12624-12631.
30. Estevanato L, Cintra D, Baldini N, etal. Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine. 2011;6:1709-1717.
31. Berg JM, Ho S, Hwang W, etal. Internalization of carbon black and maghemite iron oxide nanoparticle mixtures leads to oxidant production. Chem Res Toxicol. 2010;23(12):1874-1882.
32. Chen W, Yi P, Zhang Y, Zhang L, Deng Z, Zhang Z. Composites of aminodextran-coated Fe3O4 nanoparticles and graphene oxide for cellular magnetic resonance imaging. ACS Appl Mater Interfaces. 2011;3(10):4085-4091.
33. Ankamwar B, Lai TC, Huang JH, etal. Biocompatibility of Fe(3)O(4) nanoparticles evaluated by in vitro cytotoxicity assays using normal, glia and breast cancer cells. Nanotechnology. 2010;21(7):75102.
34. Foy SP, Labhasetwar V. Oh the irony: Iron as a cancer cause or cure? Biomaterials. 2011;32(35):9155-9158.
35. Monge-Fuentes V, Garcia MP, Tavares MC, etal. Biodistribution and biocompatibility of DMSA-stabilized maghemite magnetic nanoparticles in nonhuman primates (Cebus spp.). Nanomedicine (Lond). 2011;6(9):1529-1544.
36. Driskell JD, Jones CA, Tompkins SM, Tripp RA. One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst. 2011;136(15):3083-3090.
37. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32(29): 7139-7150.
38. Jans H, Liu X, Austin L, Maes G, Huo Q. Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. Anal Chem. 2009;81(22):9425-9432.
39. Satishkumar R, Vertegel AA. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro. Nanotechnology. 2011;22(50):505103.
40. Soler MA, Lima EC, Nunes ES, etal. Spectroscopic study of maghemite nanoparticles surface-grafted with DMSA. J Phys Chem A. 2011; 115(6):1003-1008.
41. Parker FS. Applications of Infrared, Raman, and Resonance Raman Spectroscopy in Biochemistry. 1st ed. New York: Springer; 1983.
42. Occhipinti E, Verderio P, Natalello A, etal. Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles. Nanoscale. 2011;3(2):387-390.
43. ATCC. Cell lines and hybridomas [homepage on the Internet]. Available from: http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CL-188&Template= cellBiology. Accessed March 5, 2012.